Company: NCEL
Filing Date: 2025-02-10
Form Type: F-3
Source: 0001213900-25-011823
Chunk: 120

Company: NewcelX Ltd.
Filing Date: 2025-02-10
Form: F-3
Chunk 120
---
 five years from the commencement of sales in the offering.

On March 20, 2024, we entered
into a securities purchase agreement in which the investors received unregistered warrants to purchase up to an aggregate of 87,500 Common
Shares at an exercise of $10.00 per share in a concurrent private placement. The common warrants were immediately exercisable upon issuance and will expire five years following the date of issuance. In addition, the Company agreed to issue H.C. Wainwright & Co., LLC placement agent warrants to purchase up to an aggregate of 12,250 Common Shares (representing 7.0% of the Common Shares sold in the offering), which will have an exercise price equal to $12.50 per share, and will be immediately exercisable from the date of issuance until the five year anniversary of the commencement of sales in the offering.

On December 13, 2022, the Company
closed a private placement offering with funds affiliated with BVF Partners L.P. (“BVF”), providing for the issuance of (i)
143,768 Common Shares at a purchase price of $0.87 per share and (ii) pre-funded warrants to purchase 143,678 Common Shares at $0.87 minus
$0.02 (CHF 0.02) per pre-funded warrant.

On September 30, 2022, we issued
129,870 Common Shares, at a purchase price of $30.80 per share, and warrants to purchase up to an aggregate of 64,935 Common Shares at
an exercise of $28.00 per share. At the closing of the offering, our existing short-term notes, with an aggregate principal balance of
$1.53 million plus all accrued interest, that were issued in August 2022, were automatically converted into 62,911 Common Shares and warrants to purchase up to 31,455 Common Shares with an
exercise price of $28.00, that are exercisable six months after their issuance and will expire five years following the date that the
warrants are initially exercisable.

On April 25, 2022, we issued warrants
to purchase up to an aggregate of 78,750 Common Shares at an exercise of $41.60 per share. The warrants will be exercisable six months
after their issuance and will expire five and a half years following their issuance. Upon the exercise of the warrants, the Company will
create the respective amount of Common Shares.

These warrants entitle to